To download Presenter Presentations please click here




Plenary Speakers Profiled

Margot Uys

Dr Alwyn Mwinga


Topic: Reducing TB morbidity and mortality in high HIV prevalence settings – community approaches to strengthening the TB cascade.

Dr Alwyn Mwinga is a physician trained at the University of Zambia and the University of London.  Following her postgraduate training at the London School of Hygiene and Tropical Medicine (LSHTM), she spent 10 years working in TB/HIV research. In recognition of her contributions to TB and HIV, she was awarded a Global Health Achievement award by the CDC’s Office of Global Health in 2007 and the PEPFAR Lifetime Achievement award by the US Office of the Global AIDS Coordinator in 2011. After 12 years working in public health, Dr. Mwinga returned to the field of research and is now Zambart’s Chief Executive Officer since May 2013. Zambart is  a Zambian research NGO, whose research efforts focus primarily on HIV and TB in large scale community-based trials. 


Dr Helen Macdonald

Department of Social Anthropology, UCT
Topic: TB and Stigma  

Anthropologist Dr Helen Macdonald has focused on gaining a more nuanced understanding of the social and political implications of TB in India and South Africa. In 2016, she was awarded a Wellcome Trust Community Engagement Grant for her TB project entitled Swallowing the World. Her co-edited volume with Ian Harper, Understanding Tuberculosis and its Control: Anthropological and Ethnographic Approaches, is due to be released in 2018.


Dr Iqbal Master

Head of department, MDR TB unit, King Dinizulu Hospital, Durban.
Topic: Treating DR TB at the coalface: challenges and successes

As Head and Clinical Manager at the MDR TB Unit at King Dinuzulu Hospital and over 23 years of working with MDR/XDR patients, he has gained invaluable knowledge and experience in managing the complexities of his patients that he will share with conference delegates. He is a member of both the Provincial and National Drug Resistant TB Advisory Committee and is involved in multiple studies in Drug Resistant TB.


Dr Nazir Ismail

National Institute of Communicable Diseases (NICD)
Topic: Finding TB and DR-TB using current and next generation technologies


Dr Ismail is the Head of the Centre for Tuberculosis incorporating the WHO supranational TB Reference Laboratory at the National Institute of Communicable Diseases/NHLS. He is a pathologist by training and is the lead tuberculosis researcher at NICD with a focus on TB epidemiology, public health responses and transmission.


Mr David Mametja

Chief Director, National Department of Health TB Control Programme.
Topic: Will we win the battle? Finding the missing TB patients in SA.

Mr Lerole David Mametja is a public health specialist and has more than 20 years of experience in this field. He was Executive Director of the Health Systems Trust (HST), a NGO supporting public-private partnerships in health. He was also Regional Health Sector Manager for RTI International (linked to University of North Carolina), overseeing its health programme in the Southern African Development Community (SADC), particularly in Mozambique, Lesotho, Swaziland and Namibia. He served as CEO of the Health and Welfare Sector Education Training Authority (HWSETA), an entity that focuses on providing training and skills development opportunities for South Africans. He holds a Masters degree in Public Health (MPH) (Health Policy and Management) from Columbia University, New York.


Prof Andreas Diacon

Stellenbosch University
Topic: The development and evaluation of novel anti-tuberculosis drugs - where to from here?


Prof Andreas Diacon, MD, PhD, is associate professor at Stellenbosch University and consultant for pulmonology at Tygerberg Academic Hospital, Cape Town. As the founder of Task Foundation he is investigating novel anti-tuberculosis agents and treatments that are likely to change tuberculosis treatment. He holds various collaborative research grants.


Prof Bavesh Kana

University of the Witwatersrand and Chair of the 4th South African TB Conference
Topic: Differentially Culturable TB Bacteria: Implications for diagnosis, treatment response and recurrent disease

Professor Bavesh Kana is the head of the University of the Witwatersrand (Wits) node of the DST/NRF Centre of Excellence for Biomedical TB Research, Johannesburg, South Africa, where he studies tuberculosis with a focus on identifying new drug targets and biomarkers to monitor treatment response and risk of disease recurrence. He obtained his PhD at Wits and has worked in several US institutions including the University of Pennsylvania, Texas A&M University, the Public Health Research Institute and Harvard Medical School. Prof. Kana was also appointed as an Early Career Scientist of the Howard Hughes Medical Institute (2012-2016) and was selected as one of the 200 top young South Africans by the Mail and Guardian newspaper. He is also involved in the development of next-generation diagnostic verification reagents for quality assurance and verification of tuberculosis molecular diagnostics. Some of the reagents developed in his laboratory are now being deployed in over 20 countries through a spinoff company started by Wits University.


Prof Gavin Churchyard

The Aurum Institute
Topic: The role of X-Ray in finding new TB cases - old school or new window of opportunity?

Prof Gavin Churchyard is the founder and Group CEO of The Aurum Institute, a not for profit, public benefit organization. He is an Honorary Professor at the University of Witwatersrand and the London School of Hygiene and Tropical Medicine.  He is the principal investigator on numerous investigator initiated TB trials conducted in South Africa and other African countries.  He has contributed to national and international guidelines for TB and HIV, and has published widely in the areas of TB and HIV treatment and prevention.


Prof Keertan Dheda

University of Cape Town
Topic: Fighting an old enemy: new approaches to TB diagnosis and management.

Keertan Dheda is Professor of Respiratory Medicine, and Head of the Division of Pulmonology at the University of Cape Town. He directs the interventional pulmonology program at UCT, which includes bronchial thermoplasty, ultrasound-guided mediastinal biopsy (EBUS TBNA) and medical thoracoscopy.
His research work focuses on the epidemiology, diagnosis, transmission, and treatment of TB. He has published over 200 peer-reviewed papers including 4 first or senior author original publications in The Lancet. He has been the recipient of several prestigious awards including the International Union Against Tuberculosis and Lung Disease Scientific Award. He has given plenary and keynote addresses at several international conferences. He is the current president of the South African Thoracic Society.


Prof Edward Nardell

Harvard Medical School
Topic: Infection control issues and HCW protection

Professor Edward Nardell is a physician researcher at Harvard Medical School, based at Brigham & Women's Hospital, Boston.  For 45 years he has studied airborne TB transmission and how to control it.  He and collaborators at the Airborne Infections Research (AIR) Facility, Mpumalanga, have shown that human to guinea pig transmission can result in transient infection, that upper room germicidal UV (GUV) is highly effective in reducing transmission, and that patients using surgical masks  is  about 56% effective to control the spread of TB.  Most effective of all interventions, the group has shown, is effective treatment. This has led to a refocused, intensified approach to institutional TB transmission control called FAST - Find cases Actively, Separate temporarily, and Treat effectively based on molecular DST


Dr Norbert Ndjeka

Director, DR-TB, TB/HIV unit, National TB Control Programme
Topic: Update on DR TB in SA and impact of treatment with Bedaquiline

Dr Norbert Ndjeka, a Specialist Family Physician, is also the Chair of the Regional Green Light Committee (rGLC) - Afro and a Member of the WHO Task Force on introduction of new and repurposed medicines for tuberculosis.
Dr Ndjeka, originally from the DRC, developed his passion for DR TB during his tenure as the Clinical Head of the Limpopo MDR-TB unit, a provincial facility that he helped established. Dr Ndjeka held a joint appointment of Senior Specialist in Family Medicine for Limpopo province and Senior Lecturer in Family Medicine under the University of Limpopo. He also served as MDR-TB and Infection Control Advisor, University Research Corporation.


gandhiDr Neel Gandhi

Emory University
Topic: Tracing of XDR and MDR TB cases in KZN and studying transmission.

Dr Gandhi, M.D is Associate Professor in the Departments of Epidemiology, Global Health and Infectious Diseases at Emory University’s Rollins School of Public Health and Emory School of Medicine. Dr. Gandhi has been engaged in clinical research in Tuberculosis and HIV co-infection since 1998.  Since 2002, Dr Gandhi has led a research team focused on epidemiology and clinical research studies to improve care for TB patients co-infected with HIV, including those with MDR and XDR TB. His research group has demonstrated that transmission of drug-resistant TB strains, in healthcare and community settings, is a major factor in driving the rapid expansion of the epidemic.  His group is now investigating the risk of developing resistance to bedaquiline, as well as drug-drug interactions with antiretroviral therapy, among pre-XDR and XDR TB patients.






5th SA TB Conference 2018

STEP UP - Let's embrace all to end TB!


For the last few centuries TB has caused millions of deaths. Over the last twenty years HIV, as terrible disease twin, accelerated both TB and HIV-related morbidity and mortality amongst affected populations. Since the availability of ART treatment regimens for HIV and co-infected patients, dramatic progress has been made towards better TB treatment outcomes and elimination of HIV. The TB programme on its own has also made steady progress over the last decade resulting in the declaration of the WHO End TB Strategy of 2014 which was approved by the World Health Assembly and called for a 90% reduction in TB deaths, 80% reduction in the TB incidence rate by 2030, compared with 2015 and in addition a reduction of the number of households that experience catastrophic costs as a result of TB disease.  Now, three years later, major advances in TB prevention and care have been made, especially in the six high burden countries (India, Indonesia, China, Nigeria, Pakistan and South Africa) yet an accelerated approach is needed to end TB, despite above 80% treatment success rates for drug sensitive TB, to ensure a more dramatic annual decline in TB incidence and prevention of TB deaths. Furthermore multidrug-resistant TB with an estimated 480 000 cases worldwide and a treatment success rate of just over 50% requires focussed interventions and an aggressive roll-out of available new drug regimens. The introduction of the WHO-recommended rapid diagnostic test for detection of TB and rifampicin-resistant TB (Xpert MTB/RIF assay) paved the way for a new era of novel diagnostic methods, yet programmatic benefits and adaptations to cash in on the advantage of rapid diagnosis is still lagging behind. South Africa has become the leader in the introduction of INH preventive therapy for people living with HIV for latent TB infection. Leadership is also required in other fields affecting progress, i.e. TB research, universal access to care and treatment, continued and energetic efforts for TB/HIV integration and TB financing.    Join us in stepping up strategies and activities to end the TB epidemic once and for all in Durban from 12 to 15 June 2018. We look forward to welcoming you there!


Margot Uys

Dr Margot Uys                                                  
5th SA TB Conference Chairperson
Head: Integrated Health Systems Strengthening
Foundation for Professional Development (FPD)

Important Dates


17 October 2017
Early Registration Opens
Abstract Submission Opens

Scholarship Application Opens


31 January 2018
Early Registration Closes
Abstract Submission Closes
Scholarship Application Closes


01 February 2018
Regular Registration Opens


31 May 2018
Regular Registration Closes


12 June 2018
On Site Registration Opens
















view more




view more




view more



view more



view more

Press Room


view more


Follow us